



Clinical Outcomes and Associated Costs of Treating Patients With Waldenström Macroglobulinemia in the First-Line Setting With Bruton Tyrosine Kinase Inhibitors

Samuel Crawford, PhD,¹ Huimin Li, MA,¹ Monika Salkar, PhD,¹ Xueting Yu, PhD,² Pam Martin, PhD²

¹AbbVie, North Chicago, IL, USA; ²Medical Decision Modeling Inc., Indianapolis, IN, USA

SUPPLEMENTAL RESULTS

Supplementary Table 1. Key Clinical and Economic Model Inputs

PARAMETER	INPUT	SOURCE	INPUT	SOURCE	INPUT	SOURCE
	Ibrutinib		Zanubrutinib		Bendamustine + Rituximab	
EFFICACY INPUTS	PFS, OS		PFS, OS		PFS, OS	
BASE CASE	76.0%/98.4%	NCT02604511 (Castillo, 2022)	78.0%/84.2%	ASPEN (Tam, 2020)	50.0%/67.4%	iNNOVATE (Dimopoulos, 2018)
ASPEN H2H	84.0%/97.4%	ASPEN (Tam, 2020)	78.0%/84.2%	ASPEN (Tam, 2020)		
SAFETY INPUTS	AE Rate		AE Rate		AE Rate	
BASE CASE						
HYPERTENSION	8.0%	Ibrutinib PI	9.0%	Zanubrutinib PI	0.0%	NR
ANEMIA	2.8%	Ibrutinib PI	7.0%	Zanubrutinib PI	5.0%	StiL (Rummel, 2013)
NEUTROPENIA	23.0%	Ibrutinib PI	22.0%	Zanubrutinib PI	69.0%	StiL (Rummel, 2013)
HEADACHE	0.0%	Ibrutinib PI	1.0%	Zanubrutinib PI	0.0%	NR
DIARRHEA	2.0%	Ibrutinib PI	3.0%	Zanubrutinib PI	0.0%	NR
PNEUMONIA	5.0%	Ibrutinib PI	11.0%	Zanubrutinib PI	3.2%	BRIGHT (Flinn, 2014)
THROMBOCYTOPENIA	8.0%	Ibrutinib PI	8.0%	Zanubrutinib PI	6.0%	StiL (Rummel, 2013)
ATRIAL FIBRILLATION	4.0%	ASPEN (Tam, 2020)	1.7%	Zanubrutinib PI	0.0%	NR
INFECTION	16.0%	Ibrutinib PI	13.0%	Zanubrutinib PI	5.9%	BRIGHT (Flinn, 2014)
FATIGUE	2.0%	Ibrutinib PI	1.0%	Zanubrutinib PI	3.6%	BRIGHT (Flinn, 2014)
RASH	1.0%	Ibrutinib PI	0.0%	Zanubrutinib PI	0.0%	NR
HEMORRHAGE	0.0%	Ibrutinib PI	3.6%	Zanubrutinib PI	0.0%	NR
ARTHRALGIA	0.0%	NR	0.0%	NR	0.0%	NR
NAUSEA	0.0%	Ibrutinib PI	0.0%	Zanubrutinib PI	1.8%	BRIGHT (Flinn, 2014)
SEPSIS	0.0%	NR	0.0%	NR	0.0%	NR
ASPEN H2H	Ibrutinib		Zanubrutinib		Bendamustine + Rituximab	
HYPERTENSION	11.0%	ASPEN (Tam, 2020)	6.0%	ASPEN (Tam, 2020)		
ANEMIA	5.0%	ASPEN (Tam, 2020)	5.0%	ASPEN (Tam, 2020)		
NEUTROPENIA	8.0%	ASPEN (Tam, 2020)	19.0%	ASPEN (Tam, 2020)		
HEADACHE	1.0%	ASPEN (Tam, 2020)	1.0%	ASPEN (Tam, 2020)		
DIARRHEA	1.0%	ASPEN (Tam, 2020)	3.0%	ASPEN (Tam, 2020)		
PNEUMONIA	7.0%	ASPEN (Tam, 2020)	1.0%	ASPEN (Tam, 2020)		
THROMBOCYTOPENIA	3.0%	ASPEN (Tam, 2020)	6.0%	ASPEN (Tam, 2020)		
ATRIAL FIBRILLATION	4.0%	ASPEN (Tam, 2020)	0.0%	ASPEN (Tam, 2020)		
INFECTION	3.0%	ASPEN (Tam, 2020)	0.0%	ASPEN (Tam, 2020)		
FATIGUE	1.0%	ASPEN (Tam, 2020)	1.0%	ASPEN (Tam, 2020)		
RASH	0.0%	ASPEN (Tam, 2020)	0.0%	ASPEN (Tam, 2020)		
HEMORRHAGE	9.0%	ASPEN (Tam, 2020)	6.0%	ASPEN (Tam, 2020)		
ARTHRALGIA	0.0%	ASPEN (Tam, 2020)	3.0%	ASPEN (Tam, 2020)		
NAUSEA	1.0%	ASPEN (Tam, 2020)	0.0%	ASPEN (Tam, 2020)		
SEPSIS	0.0%	NR	0.0%	NR		
COST INPUTS ^a	Cost					
WM ANNUAL HCRU-COSTS						
PROGRESSION-FREE DISEASE	\$714					
PROGRESSED DISEASE	\$1,394					
ADVERSE EVENT COSTS						
HYPERTENSION	\$5,417	Munir, 2023				
ANEMIA	\$8,800	Munir, 2023				
NEUTROPENIA	\$14,529	Munir, 2023				
HEADACHE	\$0	Assumption				
DIARRHEA	\$8,576	Munir, 2023				
PNEUMONIA	\$9,427	Chatterjee, 2021				
THROMBOCYTOPENIA	\$14,529	Munir, 2023				
ATRIAL FIBRILLATION	\$11,894	Munir, 2023				
INFECTION	\$10,801	Munir, 2023				
FATIGUE	\$744	Munir, 2023				
TUMOR LYSIS SYNDROME	\$23,311	Munir, 2023				
RASH	\$5,891	Munir, 2023				
HEMORRHAGE	\$27,071	Munir, 2023				
ARTHRALGIA	\$6,871	McGregor, 2023				
NAUSEA	\$7,962	McGregor, 2023				
SEPSIS	\$20,851	Chatterjee, 2021				

^aAll costs are inflated to May 2023.
AE, adverse event; H2H, head-to-head; NR, not reached; OS, overall survival; PFS, progression-free survival; PI, prescribing information.